StreetInsider.com News Articles

WBB Securities Upgrades Turn Therapeutics (TTRX) to Hold

Fri, 23 Oct 2026 07:18:18 -0400

(Updated - October 23, 2026 7:18 AM EDT)

WBB Securities analyst Karen Sterling upgraded Turn Therapeutics (NASDAQ: TTRX) from Sell to Hold, PT $10.00.

The analyst comments "Shares of Turn Therapeutics have lost ground in recent weeks, retreating from an intraday high of $16.45 on September 18 to current levels around $10.00. We believe the stock is fairly valued at this price and therefore upgrade our rating from Sell to Hold. We expect the encouraging initial clinical signals from a July 2026 interim analysis of the Company’s ongoing Phase 2 trial in moderate-to-severe atopic dermatitis to be confirmed in the final data

WBB Securities Upgrades Turn Therapeutics (TTRX) to Hold

Fri, 23 Oct 2026 07:18:18 -0400

(Updated - October 23, 2026 7:18 AM EDT)

WBB Securities analyst Karen Sterling upgraded Turn Therapeutics (NASDAQ: TTRX) from Sell to Hold, PT $10.00.

WBB Securities Upgrades Turn Therapeutics (TTRX) to Hold

Fri, 23 Oct 2026 07:18:18 -0400

(Updated - October 23, 2026 7:18 AM EDT)

WBB Securities analyst Karen Sterling upgraded Turn Therapeutics (NASDAQ: TTRX) from Sell to Hold, PT $10.00.

WBB Securities Upgrades Turn Therapeutics (TTRX) to Hold

Fri, 23 Oct 2026 07:18:18 -0400

(Updated - October 23, 2026 7:18 AM EDT)

WBB Securities analyst Karen Sterling upgraded Turn Therapeutics (NASDAQ: TTRX) from Sell to Hold, PT $10.00.

U.S. Bancorp | BTIG to Host Turn Therapeutics for Virtual Fireside Chat

Wed, 21 Oct 2026 16:01:00 -0400

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)-- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief Executive Officer, and Stephen M. Hahn, M.D., Executive Clinical and Regulatory Lead, will join in a U.S. Bancorp | BTIG virtual fireside chat as follows:

Date: Wednesday, October 28, 2026
Time: 10:00 AM ET

The fireside chat, "Building a Program for Patient Access in Atopic Dermatitis,” will focus on the company’s strategy for developing GX-03, its lead investigational therapy, in line with its mission to increase access to effective medicines for high-need

U.S. Bancorp | BTIG to Host Turn Therapeutics for Virtual Fireside Chat

Wed, 21 Oct 2026 16:01:00 -0400

Date: Wednesday, October 28, 2026
Time: 10:00 AM ET

Form ARS Turn Therapeutics Inc. For: Dec 31

Mon, 19 Oct 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20261019/27204050.html

Form DEF 14A Turn Therapeutics Inc. For: Nov 30

Mon, 19 Oct 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20261019/27203889.html

Form 8-K Turn Therapeutics Inc. For: Oct 06

Wed, 07 Oct 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20261007/27157408.html

Lucid Capital Markets Starts Turn Therapeutics (TTRX) at Buy

Thu, 24 Sep 2026 06:13:35 -0400

Lucid Capital Markets analyst Dev Prasad initiates coverage on Turn Therapeutics (NASDAQ: TTRX) with a Buy rating and a price target of $24.00.

The analyst comments "We initiate coverage of Turn Therapeutics with a Buy rating and $24 price target. Our investment thesis centers on GX-03, a non-steroidal topical candidate with potential applications across atopic dermatitis (AD), onychomycosis and hidradenitis suppurativa (HS). The ongoing Stage 2 AD study is the principal near-term value driver, prospectively evaluating the encouraging Stage 1 findings in patients with moderate-to-severe lesions and severe pruritus. Although the initial subgroup analysis was exploratory, the magnitude of treatment separation

Lucid Capital Markets Starts Turn Therapeutics (TTRX) at Buy

Thu, 24 Sep 2026 06:13:35 -0400

Lucid Capital Markets analyst Dev Prasad initiates coverage on Turn Therapeutics (NASDAQ: TTRX) with a Buy rating and a price target of $24.00.

WBB Securities Downgrades Turn Therapeutics (TTRX) to Sell

Mon, 14 Sep 2026 09:28:11 -0400

WBB Securities analyst Karen Sterling downgraded Turn Therapeutics (NASDAQ: TTRX) from Hold to Sell.

For an analyst ratings summary and ratings history on Turn Therapeutics click here. For more ratings news on Turn Therapeutics click here.

Shares of Turn Therapeutics closed at $12.69 yesterday.

Form 8-K Turn Therapeutics Inc. For: Sep 10

Thu, 10 Sep 2026 08:11:00 -0400

si-local-file:///var/storage/secattach/20260910/27045556.html

Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum

Thu, 10 Sep 2026 08:00:00 -0400

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)-- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief Executive Officer, and Stephen M. Hahn, M.D., Executive Clinical and Regulatory Lead, will present at the Stifel 2026 Virtual Immunology and Inflammation Forum as follows:

Date: September 23, 2026
Time: 1:30 PM ET

The presentation will provide a detailed look at the Company’s atopic dermatitis clinical program, including its pruritus-focused stage 2 enrichment strategy and emerging findings across distinct patient populations. These include patients with moderate-severe baseline pruritus, as well as a

Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum

Thu, 10 Sep 2026 08:00:00 -0400

Date: September 23, 2026
Time: 1:30 PM ET

Form D Turn Therapeutics Inc.

Wed, 26 Aug 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260826/26982394.html

Turn Therapeutics publishes GX-03 skin inflammation study in mice

Thu, 20 Aug 2026 08:04:47 -0400

Turn Therapeutics Inc. (Nasdaq: TTRX) announced the publication of peer-reviewed research showing that its investigational topical therapy GX-03 reduced several inflammatory markers in a mouse model of atopic dermatitis-like skin disease.

The study, published in the journal Life, evaluated 40 mice that received either no pretreatment or four days of topical GX-03 before exposure to Staphylococcus aureus, a bacterial challenge known to trigger atopic dermatitis-like inflammation. Following predefined exclusions, 18 animals per group were included in the final analysis.

Animals pretreated with GX-03 showed a 66% reduction in clinical dermatitis severity compared with untreated controls. The study recorded reductions in IL-36α by

Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch

Thu, 20 Aug 2026 08:00:00 -0400

In-vivo study showed GX-03 reduced IL-36, a key early driver of the inflammatory cascade, by approximately 50%, IL-31, a major driver of itch, by nearly 68%, and IL-4, an important inflammatory cytokine, by 16.7%

Findings support Turn’s approach of acting earlier in the inflammatory process, before inflammation becomes fully established

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)-- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing localized therapies for inflammatory and infectious skin diseases, today announced the publication of new peer-reviewed research providing in-vivo evidence that its lead investigational therapy, GX-03, selectively reduces several important inflammatory signals associated with

Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch

Thu, 20 Aug 2026 08:00:00 -0400

Findings support Turn’s approach of acting earlier in the inflammatory process, before inflammation becomes fully established

Form 8-K Turn Therapeutics Inc. For: Aug 13

Tue, 18 Aug 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260818/26941114.html

Form 8-K Turn Therapeutics Inc. For: Aug 14

Mon, 17 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260817/26938118.html

Form 10-Q Turn Therapeutics Inc. For: Jun 30

Wed, 12 Aug 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260812/26913863.html

Form 8-K Turn Therapeutics Inc. For: Aug 12

Wed, 12 Aug 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260812/26913678.html

Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results

Wed, 12 Aug 2026 16:30:00 -0400

Interim Analysis Supports Expansion of GX-03 Phase 2 Study to a Broader Population of Atopic Dermatitis Patients, Including Patients with Moderate-to-Severe Lesions but Lower Overall Disease Extent

Dr. Stephen M. Hahn, Former FDA Commissioner, Appointed Executive Clinical and Regulatory Lead

First Peer-Reviewed Publication Shows GX-03 Significantly Reduced Skin Inflammation in Preclinical Study

Company Plans to Expand GX-03 Pipeline into Hidradenitis Suppurativa, with First Patient Dosing Targeted for Q2 2027

Phase 2 Enrollment Expected to Complete in Fourth Quarter of 2026; Company Expects Cash to Fund Operations into Third Quarter of 2027

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)-- Turn Therapeutics

Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results

Wed, 12 Aug 2026 16:30:00 -0400

Interim Analysis Supports Expansion of GX-03 Phase 2 Study to a Broader Population of Atopic Dermatitis Patients, Including Patients with Moderate-to-Severe Lesions but Lower Overall Disease Extent

Dr. Stephen M. Hahn, Former FDA Commissioner, Appointed Executive Clinical and Regulatory Lead

First Peer-Reviewed Publication Shows GX-03 Significantly Reduced Skin Inflammation in Preclinical Study

Company Plans to Expand GX-03 Pipeline into Hidradenitis Suppurativa, with First Patient Dosing Targeted for Q2 2027

Phase 2 Enrollment Expected to Complete in Fourth Quarter of 2026; Company Expects Cash to Fund Operations into Third Quarter of 2027

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)-- Turn Therapeutics